Ebenbuild's Innovative Funding to Revolutionize Respiratory Care
Ebenbuild Secures Funding to Enhance Digital Twin Technology
Ebenbuild, a pioneering force in respiratory health technology, has successfully secured Euro 2.3 million from the prestigious European Innovation Council (EIC) Accelerator program. This funding will significantly propel the development and launch of their ambitious digital twin platform, which aims to optimize clinical and commercial applications in respiratory care.
Market Potential of Digital Twin Platforms
The digital twin technology is set to target the expansive in silico trials market, estimated at Euro 15 billion. This innovative approach has the potential to reshape critical decision-making in Intensive Care Units (ICUs), marking a pivotal moment for respiratory health management. With their unique software, Twinhale, Ebenbuild endeavors to redefine how pulmonary drug delivery is approached, significantly benefiting healthcare providers and patients alike.
The Twinhale Platform: A Game Changer
Twinhale stands out as the very first scalable simulation tool designed for patient-specific, physiologically accurate predictions of drug deposition in the lungs. By leveraging Ebenbuild’s proprietary platform, pharmaceutical and medtech companies can now access a cost-effective method for digitally simulating drug delivery in the lungs. This innovation is not only aimed at reducing trial failure rates but also at expediting time-to-market for essential medications.
Successful Collaborations and Validation
In the pursuit of excellence, Ebenbuild has already conducted pilot studies utilizing Twinhale with notable industry players, PARI Pharma and Pieris Pharmaceuticals. The successful validation studies have demonstrated Twinhale's capability to predict the localized drug deposition with remarkable precision, far surpassing existing models. This groundbreaking technology provides crucial insights that are typically inaccessible through traditional testing methods.
Support and Future Directions
Fully supported by investors like HTGF and Bayern Kapital, Ebenbuild is on a trajectory to penetrate the rapidly growing Euro 5 billion in silico trials market. Beyond the initial funding, the EIC has pledged to invest up to €10 million in future equity financing rounds, solidifying their commitment to fostering innovation in the field.
Vision for the Future of Respiratory Health
Dr. Kei Müller, CEO and Co-founder of Ebenbuild, shared a compelling vision for the organization: “Our goal is to establish itself as the leading health intelligence platform for managing respiratory diseases. Twinhale marks just the beginning of our journey. We envision our core platform powering future regulated products geared towards optimizing mechanical ventilation and managing chronic respiratory diseases.”
Innovating Decision-Making in Drug Development
Dr. Maximilian Grill, Head of In Silico Trials at Ebenbuild, expressed enthusiasm for how Twinhale reduces attrition rates in respiratory drug development. He highlighted the generation of unique datasets that could potentially lead to regulatory acceptance, paving the way for innovative strategies in companion diagnostics.
A Comprehensive Roadmap Ahead
Ebenbuild is not stopping with Twinhale. Their ambitious roadmap includes expanding from preclinical simulations to clinical-grade decision support systems. The company is also developing software aimed at optimizing mechanical ventilation for patients facing lung complications, tapping into a substantial Euro 10 billion market that demands rapid feedback and tangible economic advantages.
About Ebenbuild
Ebenbuild is at the forefront of digital health technology, specializing in creating precise computer models—termed digital twins—of lungs using patient-specific data. The innovative toolset is founded on a combination of physics-based simulation, AI, and data science to assist decision-makers in life sciences and healthcare. By enhancing the understanding of respiratory diseases and individual pathophysiology, Ebenbuild aims to facilitate improved patient outcomes and de-risk the development of inhaled drugs.
Contact Information
For more information, you can reach out to Ebenbuild directly:
Company Contact
Dr. Jonas Biehler
Email: biehler@ebenbuild.com
Media Inquiries
Contact: akampion
Dr. Ludger Wess / Ines-Regina Buth
Email: info@akampion.com
Phone: +49 40 88 16 59 64 / +49 30 23 63 27 68
Frequently Asked Questions
What is Ebenbuild's main focus?
Ebenbuild focuses on developing digital twin technology for respiratory health to improve clinical decision-making and drug development.
What is Twinhale?
Twinhale is a simulation tool by Ebenbuild that enables accurate predictions of drug deposition in the lungs based on patient-specific data.
Who has funded Ebenbuild?
Ebenbuild has secured funding from the EIC Accelerator program, along with investments from HTGF, Bayern Kapital, and angel investors.
What market is Ebenbuild targeting?
Ebenbuild is targeting the rapidly growing Euro 15 billion in silico trials market and the clinical decision support systems market estimated at over €300 billion by 2030.
How does Twinhale benefit pharmaceutical companies?
Twinhale provides a cost-efficient platform for simulating pulmonary drug delivery, potentially reducing time-to-market and trial failure rates.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
